157 related articles for article (PubMed ID: 36795254)
1. Reappraisal of Malignant Risk Assessment for Small (≤20 mm) Non-functioning Pancreatic Neuroendocrine Tumors.
Nanno Y; Toyama H; Matsumoto I; Uemura J; Asari S; Goto T; Lee D; Murakami T; Komatsu S; Yanagimoto H; Kido M; Ajiki T; Okano K; Takeyama Y; Fukumoto T
Ann Surg Oncol; 2023 Jun; 30(6):3493-3500. PubMed ID: 36795254
[TBL] [Abstract][Full Text] [Related]
2. Prediction of lymph node metastasis in pancreatic neuroendocrine tumors by contrast enhancement characteristics.
Mizumoto T; Toyama H; Terai S; Mukubou H; Yamashita H; Shirakawa S; Nanno Y; Sofue K; Kido M; Ajiki T; Fukumoto T
Pancreatology; 2017; 17(6):956-961. PubMed ID: 28964660
[TBL] [Abstract][Full Text] [Related]
3. Pattern and clinical predictors of lymph node involvement in nonfunctioning pancreatic neuroendocrine tumors (NF-PanNETs).
Partelli S; Gaujoux S; Boninsegna L; Cherif R; Crippa S; Couvelard A; Scarpa A; Ruszniewski P; Sauvanet A; Falconi M
JAMA Surg; 2013 Oct; 148(10):932-9. PubMed ID: 23986355
[TBL] [Abstract][Full Text] [Related]
4. Computed Tomography Features Predictive of Lymph Node Involvement in Patients With a Nonfunctioning Pancreatic Neuroendocrine Tumor.
Choi SH; Kim HJ; Kim SY; Byun JH; Kim KW; Song KB; Kim SC; Kim MH
Pancreas; 2017 Sep; 46(8):1056-1063. PubMed ID: 28787330
[TBL] [Abstract][Full Text] [Related]
5. Pancreatic neuroendocrine tumors: Correlation between the contrast-enhanced computed tomography features and the pathological tumor grade.
Takumi K; Fukukura Y; Higashi M; Ideue J; Umanodan T; Hakamada H; Kanetsuki I; Yoshiura T
Eur J Radiol; 2015 Aug; 84(8):1436-1443. PubMed ID: 26022520
[TBL] [Abstract][Full Text] [Related]
6. Role of chromogranin A-derived fragments after resection of nonfunctioning pancreatic neuroendocrine tumors.
Andreasi V; Partelli S; Manzoni MF; Muffatti F; Di Filippo L; Crippa S; Corti A; Falconi M
J Endocrinol Invest; 2022 Jun; 45(6):1209-1217. PubMed ID: 35122631
[TBL] [Abstract][Full Text] [Related]
7. Serum Elastase 1 Level as a Risk Factor for Postoperative Recurrence in Patients with Well-Differentiated Pancreatic Neuroendocrine Neoplasms.
Nanno Y; Toyama H; Zen Y; Akita M; Ando Y; Mizumoto T; Ueda Y; Ajiki T; Okano K; Suzuki Y; Fukumoto T
Ann Surg Oncol; 2018 Oct; 25(11):3358-3364. PubMed ID: 30054822
[TBL] [Abstract][Full Text] [Related]
8. Morphologic Variants of Pancreatic Neuroendocrine Tumors: Clinicopathologic Analysis and Prognostic Stratification.
Xue Y; Reid MD; Pehlivanoglu B; Obeng RC; Jiang H; Memis B; Lui SK; Sarmiento J; Kooby D; Maithel SK; El-Rayes B; Basturk O; Adsay V
Endocr Pathol; 2020 Sep; 31(3):239-253. PubMed ID: 32488621
[TBL] [Abstract][Full Text] [Related]
9. Predictive value of preoperative peripheral blood neutrophil/lymphocyte ratio for lymph node metastasis in patients of resectable pancreatic neuroendocrine tumors: a nomogram-based study.
Tong Z; Liu L; Zheng Y; Jiang W; Zhao P; Fang W; Wang W
World J Surg Oncol; 2017 May; 15(1):108. PubMed ID: 28558772
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathological characteristics and risk factors for recurrence of well-differentiated pancreatic neuroendocrine tumors after radical surgery: a case-control study.
Zhang P; Li YL; Qiu XD; Luo J; Shi YF; Sun YL; Su F; Qi ZR; Tan HY
World J Surg Oncol; 2019 Apr; 17(1):66. PubMed ID: 30975157
[TBL] [Abstract][Full Text] [Related]
11. Cadherin 17 is frequently expressed by 'sclerosing variant' pancreatic neuroendocrine tumour.
Johnson A; Wright JP; Zhao Z; Komaya T; Parikh A; Merchant N; Shi C
Histopathology; 2015 Jan; 66(2):225-33. PubMed ID: 25307987
[TBL] [Abstract][Full Text] [Related]
12. CT Radiogenomic Characterization of the Alternative Lengthening of Telomeres Phenotype in Pancreatic Neuroendocrine Tumors.
McGovern JM; Singhi AD; Borhani AA; Furlan A; McGrath KM; Zeh HJ; Bahary N; Dasyam AK
AJR Am J Roentgenol; 2018 Nov; 211(5):1020-1025. PubMed ID: 30160983
[TBL] [Abstract][Full Text] [Related]
13. A Single-center Prospective Observational Study Investigating the Accuracy of Preoperative Diagnostic Procedures in the Assessment of Lymph Node Metastases in Nonfunctioning Pancreatic Neuroendocrine Tumors.
Partelli S; Muffatti F; Andreasi V; Giannone F; Rossi G; Palumbo D; Mapelli P; Schiavo Lena M; Arcidiacono PG; De Cobelli F; Picchio M; Doglioni C; Falconi M
Ann Surg; 2022 Nov; 276(5):921-928. PubMed ID: 35930017
[TBL] [Abstract][Full Text] [Related]
14. Surgery Versus Surveillance for Well-Differentiated, Nonfunctional Pancreatic Neuroendocrine Tumors: An 11-Year Analysis of the National Cancer Database.
Assi HA; Mukherjee S; Kunz PL; Machiorlatti M; Vesely S; Pareek V; Hatoum H
Oncologist; 2020 Feb; 25(2):e276-e283. PubMed ID: 32043766
[TBL] [Abstract][Full Text] [Related]
15. Pancreatic High-Grade Neuroendocrine Neoplasms in the Korean Population: A Multicenter Study.
Kim H; An S; Lee K; Ahn S; Park DY; Kim JH; Kang DW; Kim MJ; Chang MS; Jung ES; Kim JM; Choi YJ; Jin SY; Chang HK; Cho MY; Kang YK; Kang M; Ahn S; Kim YW; Hong SM;
Cancer Res Treat; 2020 Jan; 52(1):263-276. PubMed ID: 31319641
[TBL] [Abstract][Full Text] [Related]
16. Pancreatic neuroendocrine tumors containing areas of iso- or hypoattenuation in dynamic contrast-enhanced computed tomography: Spectrum of imaging findings and pathological grading.
Hyodo R; Suzuki K; Ogawa H; Komada T; Naganawa S
Eur J Radiol; 2015 Nov; 84(11):2103-9. PubMed ID: 26321494
[TBL] [Abstract][Full Text] [Related]
17. Prognostic Role of Examined and Positive Lymph Nodes after Distal Pancreatectomy for Non-Functioning Neuroendocrine Neoplasms.
Guarneri G; de Mestier L; Landoni L; Partelli S; Gaujoux S; Andreasi V; Nessi C; Dokmak S; Fontana M; Dousset B; Ruszniewski P; Bassi C; Falconi M; Sauvanet A
Neuroendocrinology; 2021; 111(8):728-738. PubMed ID: 32585667
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of Survival Following Surgical Resection for Small Nonfunctional Pancreatic Neuroendocrine Tumors.
Sugawara T; Rodriguez Franco S; Kirsch MJ; Colborn KL; Ishida J; Grandi S; Al-Musawi MH; Gleisner A; Del Chiaro M; Schulick RD
JAMA Netw Open; 2023 Mar; 6(3):e234096. PubMed ID: 36976561
[TBL] [Abstract][Full Text] [Related]
19. A novel risk factor panel predicts early recurrence in resected pancreatic neuroendocrine tumors.
Wang WQ; Zhang WH; Gao HL; Huang D; Xu HX; Li S; Li TJ; Xu SS; Li H; Long J; Ye LY; Wu CT; Han X; Wang XH; Liu L; Yu XJ
J Gastroenterol; 2021 Apr; 56(4):395-405. PubMed ID: 33742253
[TBL] [Abstract][Full Text] [Related]
20. Pancreatic neuroendocrine tumors with somatostatin expression and paraganglioma-like features.
Konukiewitz B; von Hornstein M; Jesinghaus M; Steiger K; Weichert W; Detlefsen S; Kasajima A; Klöppel G
Hum Pathol; 2020 Aug; 102():79-87. PubMed ID: 32668277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
